Enadenotucirev Clinical

A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE)

Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion*, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo. Journal for ImmunoTherapy of Cancer (2019) 7:20

Kate WrightEnadenotucirev Clinical

Phase 1 Study of Intravenous Administration of the Chimeric Adenovirus Enadenotucirev in Patients Undergoing Primary Tumor Resection

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.  
Journal for ImmunoTherapy of Cancer2017 5:71

Nitin JainEnadenotucirev Clinical

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)

Séan M. O’Cathail, Steven Davis, Jane Holmes, Richard Brown, Kerry Fisher, Leonard Seymour, Richard Adams, James Good, David Sebag-Montefiore, Tim Maughan and Maria A. Hawkins*
Radiation Oncology (2020) 15:151

Kate WrightEnadenotucirev Clinical

Sign up to our mailing list

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu